08:11 AM EST, 11/25/2024 (MT Newswires) -- Alnylam Pharmaceuticals ( ALNY ) said Monday the US Food and Drug Administration has accepted its supplemental new drug application for vutrisiran, an investigational RNAi therapeutic for the treatment of ATTR amyloidosis with cardiomyopathy.

The FDA has set a target action date of March 23 and is not planning to hold an advisory committee meeting at this time to review the application, Alnylam said.

Vutrisiran, the generic name for Amvuttra, is currently approved for treating the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.